LDL Cholesterol – Medxy AI

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Cardiology Internal Medicine news

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

By MedXY 03/21/2026

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefining the boundaries of LDL-C reduction and patient care in atherosclerotic disease.

Cardiology news Pediatrics

Why Universal Cholesterol Screening for Familial Hypercholesterolaemia Should Wait Until Age One

By MedXY 01/03/2026

A landmark Norwegian study reveals that umbilical cord LDL-C levels overlap significantly between FH and non-FH newborns, making birth screening unreliable. In contrast, LDL-C becomes highly discriminative after age one, suggesting that universal screening should be deferred to early childhood.

Cardiology news

Genetic Insights into LDL Cholesterol and Coronary Artery Disease Risk Across Diverse Global Populations

By MedXY 10/30/2025

A large-scale multi-ancestry genetic study confirms consistent associations between LDL cholesterol levels and coronary artery disease risk across six global ancestries, highlighting the generalizability of LDL-C lowering interventions beyond European populations.

Cardiology Neurology Specialties

Long-Term Stroke Risk in Healthy Women: The Predictive Role of hsCRP, LDL Cholesterol, and Lipoprotein(a)

By MedXY 10/22/2025

A 30-year prospective study reveals that elevated hsCRP, LDL cholesterol, and lipoprotein(a) levels independently and collectively increase the risk of ischaemic stroke in healthy women, advocating for early biomarker screening in stroke prevention.

Cardiology Clinical Updates news

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

By MedXY 09/24/2025

This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.

Cardiology news Specialties

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

By MedXY 09/21/2025

The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.

Cardiology news Specialties

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

By MedXY 09/07/2025

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Clinical Updates Diabetes & Endocrinology Specialties

Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes

By MedXY 08/24/2025

A 12-week randomized controlled trial demonstrated that supplementation with berberine plus cinnamon significantly lowers fasting blood sugar, HbA1c, and LDL cholesterol in patients with type 2 diabetes, offering potential for improved cardiometabolic risk management.

Cardiology Clinical Updates news Specialties

Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial

By MedXY 08/17/2025

Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.